Rating: Neutral | Target Price: HKD 62–67 (base-case rNPV/SOTP) | Current Price: HKD 67.05 (close on 2026-10-30) Margin of safety: approx. -8% (lower bound of target range HKD 62 is below current price HKD 67.05) | Time horizon: 12 months | Market cap: HKD 20.03 billion (298.7 million shares)
Keymed Biosciences is a rare dual-engine Biotech among Hong Kong 18A companies, combining "in-house autoimmune commercialization + global out-licensing in oncology/bispecifics": Kangyueda (stapokibart) is delivering genuine volume growth under NRDL reimbursement (approximately RMB 660 million in product revenue for the first three quarters of 2026, +227% YoY), CMG901 achieved the first positive Phase III OS topline globally for a CLDN18.2 ADC, with AstraZeneca advancing US and China BLA filings in 2026Q4, and the NewCo pathway has been cash-validated by Gilead's USD 257 million upfront payment. In terms of quality, it belongs to the first tier. However, this report's independently built rNPV/SOTP base-case fair value is HKD 64.7 per share (range 62–67); the current price of HKD 67.05 represents a premium of roughly 3.6%—the current price already reflects "CM310 peak of approximately RMB 4.5 billion + CMG901 peak realization of USD 4 billion," making it reasonably full rather than mispriced; the odds across the three scenarios are roughly symmetric (bear 36–42 / base 62–67 / bull 92–100 HKD). Key constraints: the 2026H1 book turnaround to profit was due to a one-off gain from the sale of Ouro, with recurring operations still loss-making; AD indication overcrowding ("red ocean") and NRDL renewal price cuts in 2027–2028; Innovent's IBI343 has already been accepted for NDA review in China ahead of CMG901, undermining its first-mover position in China. Conclusion: good quality, fair price—do not chase at current levels; wait for catalyst validation or a pullback.
NRDL (effective 2026-01) + Essential Medicines List (effective 2026-09, opening county-level primary care) + adolescent AD approval (2026-10-16, population expanded to age 12+) constitute the access foundation for continued ramp in 2027; sell-side forecasts 2027 sales of RMB 1.79–2.13 billion. Two caveats: Q3 momentum includes seasonal allergic rhinitis (the only IL-4Rα approved globally for that indication) pollen-season contribution, so sequential extrapolation requires caution; this report's base-case peak of RMB 4.1 billion (around 2033) is a model assumption (benchmarked against Dupixent's China scale of roughly RMB 4.5 billion in 2025), implying a mature-stage share of approximately 35–45%—whether that holds after competitor entry in 2027–2028 must be validated against the C5 competitive scenario.
Excluding the one-off gain, 2026H1 recurring loss was approximately RMB 130–160 million (range estimated by this report due to disclosure limitations on the tax treatment of the Ouro gain); collaboration revenue is recognized at milestone timing and is volatile (-31.9% YoY in 2026H1), with high single-customer (AstraZeneca linkage) concentration. We judge that the cash-flow quality of BD revenue is genuine (converted to cash milestones from 2026; historical non-cash NewCo equity consideration was RMB 192 million/RMB 125 million in 2024/2025 respectively, zero in 2026H1), but it cannot be extrapolated as recurring profit.
Using a USD 4 billion peak (midpoint of AZ guidance) × 8% royalty (terms undisclosed; this report's assumption; Guosen Securities cites a "low-double-digit sales share," i.e., the actual figure could be higher) × 70% KYM entitlement, discounted, rNPV is approximately RMB 4.4 billion, about one-third of the SOTP pipeline value. Three risks must be weighted equally: ① one of the dual primary endpoints, PFS, missed significance and the trial was open-label—a realistic possibility of FDA information requests/CRL/label narrowing; ② Innovent's IBI343 (Takeda holds ex-China rights) announced positive Phase III interim analysis and NMPA acceptance with Priority Review in 2026-06—CMG901 will most likely lose first-mover advantage in the China 3L+ market, and the probability of realizing the China portion of peak guidance is revised down; ③ AZ's commercialization execution is outside the company's control.
Back-solving from this report's SOTP structure: market cap − net cash = pipeline rNPV of approximately RMB 14.42 billion, about 4.3% above the independently built base case, implying a CM310 peak of approximately RMB 4.5 billion—a five-fold-level forward expectation versus reality (2026E product revenue of approximately RMB 900 million), but relative to Dupixent's China scale and first-mover position, it is "reasonably full" rather than narrative overreach. Sensitivity cuts both ways: if CMG901 royalty rises from 8% to 11% (moving toward Guosen's "low-double-digit" figure), the base case rises to approximately HKD 71 and the current price becomes a discount; if a STAR Market issuance proceeds at the customary 10–15% scale, dilution of approximately 9–13% would lower the base case to approximately HKD 58—the two effects are opposite in direction and roughly offset. Upside requires catalyst-driven upward revisions to assumptions, not valuation mean reversion.
The price-cut tail risk is corroborated by third-party data (Dupixent -45% precedent), but two offsets: Qyuns withdrew talicibart's AD application in 2026-07, and review setbacks could delay competitor timing; Huatai Securities (2025-11) believes stapokibart's simple renewal price cut may be relatively mild, and mandatory Essential Medicines List stocking brings primary-care incremental volume. Under a dual volume-price pressure scenario (price cut of 30–45% and volume growth of +0–10%), 2028 product revenue would be 20–30% below one-sided extrapolation; under a mild renewal (-15%), volume growth offsets the impact and the effect is limited.
The dosing frequency (one injection every six months) is a clear advantage over Dupixent (Q2W) and Tezspire (Q4W), an adherence selling point for a next-generation autoimmune blockbuster; but competition is also accelerating: Tezspire (2025 global sales of USD 1.478 billion) is expanding into CRSwNP/asthma, and AbbVie's proposed acquisition of Apogee for approximately USD 10.9 billion (long-acting IL-13, AD Phase II) shows MNCs' willingness to pay for long-acting agents, meaning CM512 must be validated with Phase III data rather than dosing convenience. This report's base-case rNPV is only RMB 1.3 billion (8% of SOTP; Keymed's economic terms under the Belenos agreement are undisclosed, conservative estimate), and it is the core upward-revision variable in the bull scenario (bull case: RMB 2 billion domestic + USD 2.5 billion overseas).
| Metric (RMB 100 million) | 2023FY | 2024FY | 2025FY | 2026H1 (latest period) |
|---|---|---|---|---|
| Operating revenue | 3.54 | 4.28 | 7.16 | 6.17 (+23.7%) |
| Of which: drug sales | — | 0.36 | 3.15 | 3.93 (+132%) |
| Of which: collaboration revenue | 3.54 | 3.92 | 4.02 | 2.24 (-31.9%) |
| Net profit attributable to parent | -3.58 | -5.15 | -5.23 | +12.17 (includes one-off gains) |
| Adjusted loss (non-IFRS, excl. share-based payments only) / recurring loss | — | -4.81 | -4.95 | approx. -1.3 ~ -1.6 (this report's estimate, excl. Ouro gain) |
| Gross margin | 89.6% | 97.2% | 87.7% | 80.8% |
| R&D expenses | 5.96 | 7.35 | 7.24 | 3.39 (-5.9%) |
| Operating cash flow | -3.04 | -7.90 | -7.12 | -2.54 |
| Capital expenditure | — | 2.08 | 3.34 | 0.77 |
| Cash + time deposits + wealth management (period end) | 27.19 | 21.56 | 19.63 | 32.42 (2026-06-30) |
| Interest-bearing debt (period end) | — | — | 7.67 | 6.77 |
| Debt-to-asset ratio (period end) | — | — | 34% | 29% |
| Net cash (this report's estimate) | — | — | — | approx. 25.64 (2026-06-30) |
Note: product revenue for the first three quarters of 2026 was approximately RMB 660 million (+227%), with Q3 single quarter approximately RMB 267 million; innovative drug companies pay no dividends; ex-items/adjusted measures as per table notes; the TTM P/E (22.5x) is contaminated by one-off gains and not meaningful for valuation.
Reasons for metric changes (items with YoY ≥ ±20%, with company explanations): 2025 revenue +67%—Kangyueda sales of RMB 315 million (+776%) plus collaboration revenue of RMB 402 million; management described it as the key year of entering "dual-wheel drive of R&D and commercialization"; cost of sales +622%—company explained as Kangyueda production costs and costs arising from out-licensing collaboration arrangements (own-product volume ramp); selling and distribution expenses +190% (RMB 111 million → 322 million)—consistent with increased Kangyueda sales, commercialization team expanded from 407 to 550+ people; 2026H1 attributable profit turnaround +RMB 1.217 billion—mainly from the RMB 1.64 billion fair-value gain on the sale of the Ouro stake (one-off); cash reserves +65% to RMB 3.242 billion—receipt of the USD 257 million upfront from the Ouro transaction; product revenue for the first three quarters +227%—company explained as "sharp increases in genuine market demand and the number of hospitals with access," driven jointly by the NRDL payment price of RMB 1,039 per vial + the Essential Medicines List (effective 2026-09).
2026H1 revenue of RMB 617 million (+23.7%): product revenue of RMB 393 million (+132%) showed strong volume growth, while collaboration revenue of RMB 224 million (-31.9%)—the prior-year period included a high base of AZ milestones of RMB 231 million, and this period's new AZ milestone (G02 first-patient dose of USD 45 million × 70% ≈ RMB 220 million) was recognized in Q1—a timing mismatch rather than weakening demand. Book net profit attributable to parent was RMB 1.217 billion, but RMB 1.64 billion of that was a one-off fair-value gain from the sale of Ouro; excluding it, recurring operations still lost approximately RMB 130–160 million—the turnaround narrative must be dissected. The cash-flow improvement is genuine: net operating outflow narrowed from RMB 181 million in the prior-year period to RMB 254 million (including AZ milestone receipts), and period-end cash of RMB 3.242 billion was a post-IPO record high. Q3 product revenue was approximately RMB 267 million, +36% QoQ, including seasonal SAR pollen-season contribution; the full-year RMB 850 million guidance requires only RMB 190 million in Q4 to be met. The selling expense ratio has fallen from 81.7% in 2025 to 55.5% (2026H1), with economies of scale beginning to emerge. The market's reaction to these results (Daiwa/CLSA subsequently raising target prices to HKD 110/104) has partially priced in the volume ramp.
Business model: Asset-light R&D + in-house commercialization + licensing monetization — a "dual-wheel" approach. In autoimmune, the company self-develops and self-markets (Kangyueda/Staquilinimab, biologics gross margin ~88%); oncology/bispecific assets are monetized via license-out deals and NewCos (Belenos, Ouro, Timberlyne, Prolium), with MNCs and overseas capital bearing global development costs while the company collects upfront payments/milestones/royalties. Recurring revenue is improving: product revenue share 8.4% in 2024 → 43.9% in 2025 → 63.6% in 1H2026.
Cash content of earnings: 2025 OCF of -RMB 712 million / adjusted loss of -RMB 495 million = 1.44 (during the loss-making period, this ratio serves as a cash-burn gauge); FCF of -RMB 1,046 million (OCF − CapEx). Marked improvement in 1H2026: OCF of -RMB 254 million (half-year), product revenue of RMB 393 million with the AZ milestone paid in cash. Recurring profitability test: 1H2026 net profit attributable to shareholders of RMB 1,217 million vs. recurring result of roughly -RMB 140 million — the 100%+ difference comes entirely from one-off equity disposals; do not be misled by the book turnaround. Meanwhile, the company's self-reported non-IFRS measure strips out only share-based payments (RMB 27.8 million), a conservative definition with no aggressive exclusions. Historically, 17–45% of licensing proceeds were received in non-cash forms such as NewCo equity (RMB 192 million in 2024 / RMB 125 million in 2025), switching to cash milestones from 2026.
Return on capital and CapEx: ROIC not applicable during the loss-making period. CapEx/depreciation = 3.4 (RMB 334 million / 98 million in 2025), reflecting capacity-expansion investment (a new 24,000 L stainless-steel production line at the Chengdu site, total capacity 21,800+24,000 L, compliant with both NMPA and FDA cGMP) — growth-oriented spending, supporting the Kangyueda ramp-up and the future CM512 launch, not a maintenance black hole.
Moat and red flags: The moat lies in first-mover advantage + market access (first domestic IL-4Rα, the only drug in both NRDL and the National Essential Drugs List, 2,200+ hospitals) and platform monetization capability (four NewCo/MNC transactions validating pricing). Red flags: ① earnings highly dependent on one-off BD gains (see Section C2); ② a single commercialized product accounts for all product revenue; ③ a single customer (AZ) represents 35.5% of 1H2026 revenue; ④ idle use-of-proceeds funds (the R&D/CapEx tranches of the 2025 placement untouched for a year) coexisting with new bank borrowings — low capital efficiency.
Consistency between words and deeds: pragmatic, high delivery rate on key commitments. Verifiable commitment-delivery pairs over the past 12 months: ① 2025 annual report committed to Kangyueda's three indications entering NRDL in 2026 → delivered (RMB 1,039 per vial; additionally entered the Essential Drugs List in July 2026); ② adolescent AD NDA accepted in January 2026 → approved on October 16, 2026; ③ CM512 Phase II read out on schedule, meeting all endpoints, with Phase III rapidly initiated; ④ Gilead's acquisition of Ouro → closed June 5, 2026, with USD 257 million received. The only blemish: of the RMB 782 million raised in the June 2025 placement, the R&D (RMB 274 million) and CapEx (RMB 195 million) tranches were entirely unspent as of June 30, 2026; only the commercialization tranche drew RMB 204 million — slow execution, but no misuse of funds.
Shareholder friendliness: neutral to dilutive. No dividends since listing; 2024 buyback of RMB 32.4 million used for RSUs (not cancelled); June 2025 placement of 19 million shares at HKD 45.48 (~6.8% dilution, 6.5% discount); August 2026 board resolution to pursue a STAR Market listing (potential dilution of 9–13%, plan undetermined); October 29, 2026 — board authorized spending ~HKD 100 million on market-price share purchases for the RSU plan, explicitly stating "the shares are severely undervalued at current market price" — a positive signal, but incentive-oriented, not a cancellation buyback.
Risk signals: Chairman and CEO roles both held by Bo Chen (management holds 25.16% via Moonshot); the company itself acknowledges deviation from CG Code provision C.2.1; non-executive director Wang Minchuan resigned in September 2026; no record of controlling-shareholder sell-downs. The company has no revenue/profit guidance culture and operates on milestone delivery — conservative by Biotech standards.
| Segment | 1H2026 Revenue Share | YoY | Commercial Logic |
|---|---|---|---|
| Drug sales (Kangyueda) | 63.6% | +132% | NRDL + Essential Drugs List-driven autoimmune product ramp; highest recurrence and predictability |
| Collaboration revenue (AZ/Aeira/Belenos milestones and services) | 36.4% | -31.9% | Licensing monetization; point-in-time recognition, large lumpy amounts, not extrapolable |
The company does not disclose gross margin by segment (consolidated 80.8%): drug sales are at the normal high end for biologics (peers at 82–84%); licensing revenue carries higher margins but its costs are booked into cost of sales. The primary profit driver is drug sales — the only recurring source of profit. Collaboration revenue, though higher-margin, fluctuated across 2024–2026 (RMB 392/402/224 million), proving it can only serve as a channel for realizing pipeline value, not a profit foundation. The different commercial logics of the two segments (product operations vs. asset monetization) call for differentiated valuation: commercialization multiples for the former, rNPV discounting for the latter (see the "Pipeline Value and Clinical Milestones" section).
Accounting red flags: ① licensing consideration received in non-cash forms such as NewCo equity (RMB 192 million in 2024, RMB 125 million in 2025; Level 3 valuation subjectivity) — moderate; switched to cash milestones from 2026; ② milestone revenue recognized at point in time + customer concentration (AZ-related deals at 32.2% of 2025 revenue, ~35.5% of 1H2026) — moderate; inherent to the business model rather than suggesting manipulation; ③ 1H2026 accounts receivable +108% (RMB 101 million → 210 million) far outpacing revenue +24% — low; normal credit terms of a rapidly scaling distributor network (60-day terms, 0.11% overdue rate), worth monitoring; ④ idle use-of-proceeds funds coexisting with bank borrowings — low. No evidence of early revenue recognition or expense capitalization: R&D fully expensed; intangibles at only 0.2% of total assets.
Inter-period consistency: Gross margin 89.6% → 97.2% → 87.7% → 80.8% — driven by rising product manufacturing and licensing cost shares, consistent with management's explanation; collaboration revenue share 100% → 91.6% → 56.1% → 36.4% — revenue mix shifting toward product sales, consistent with the "dual-wheel drive" narrative; non-cash consideration revenue RMB 192 million → 125 million → 0 — not separately explained by the company, but directionally consistent with BD model maturation; operating cash flow narrowing in 1H2026 after three consecutive years of net outflows — consistent. Overall judgment: no notable signs of financial engineering in the extracted financials; revenue recognition definitions and disclosure consistency are sound; the main blemishes are the point-in-time nature of BD revenue and its non-cash history.
Market data (close of October 30, 2026): Share price HKD 67.05, market cap HKD 20.03 billion (RMB 16.987 billion); 52-week range HKD 46.34–87.20, current price -23.1% from the high, +25.4% YTD. PE(TTM) 22.5x — contaminated by one-off gains, not meaningful; PS(TTM) ~20.4x (our estimate); PB 4.34x (60th percentile over 5 years, 1st percentile over 1 year — the 1H2026 net asset jump is due to the one-off Ouro gain; percentiles are indicative only). Peer comparison (PS basis):
CM AB's PS sits in the same band as Akeso (21.3x), which shares its loss-making platform narrative, about 1.1–1.2x above the already-profitable Innovent/RemeGen (9–9.5x) — reflecting the loss-stage pipeline option premium. On FY2027E revenue of RMB 1.5–1.8 billion, forward PS is ~10.3x, implying the market is pricing the company as "delivering a year early Innovent/RemeGen's current multiples."
Market-implied expectations: Market cap − net cash (RMB 2.564 billion) = pipeline rNPV of ~RMB 14.42 billion, 4.3% above our bottom-up base case of RMB 13.83 billion — the current price requires "CM310 peak of ~RMB 4.5 billion and CMG901 USD 4 billion peak to materialize largely simultaneously," whereas in reality CM310's ramp is genuine but competition intensifies from 2027, and CMG901's data are validated while royalty terms are undisclosed and Chinese first-mover status has changed hands. In one sentence: the current price fully prices the base case, leaving no discount for the bear case and no excess for the bull case.
Three-layer value (EPV): Asset value ~HKD 23.1/share (net cash of HKD 10.12/share + conservative discounting of Kangyueda's approved indications); EPV with zero growth ~HKD 19.5/share (2026E product revenue ~RMB 950 million × 25% FCF margin = FCFF ~RMB 238 million, 10% discount rate, plus net cash); the gap between current price and EPV, ~HKD 47.5/share (~71% of the current price), is the option value of the entire pipeline portfolio — for a loss-stage innovative-drug company, EPV only captures the existing run rate; the pricing tools are the rNPV/SOTP in the "Pipeline Value and Clinical Milestones" section, not EPV. A high growth-option share does not by itself support an overvaluation conclusion; scenario distribution matters.
Three scenarios and odds (rNPV/SOTP, consistent with the pipeline value section):
| Scenario | Probability | Fair Range (HKD) | vs. Current Price | Key Drivers |
|---|---|---|---|---|
| Bear | 25% | 36–42 (midpoint 39) | -46% ~ -37% | Red-ocean price war (CM310 peak RMB 2.5bn) + BLA setback (USD 2.5bn/6%/PoS 0.65) + CM512 delays |
| Base | 50% | 62–67 (midpoint 64.7) | -7.5% ~ -0.1% | CM310 peak RMB 4.1bn; CMG901 USD 4bn/8%; CM512 RMB 1.5bn domestic + USD 1.5bn overseas |
| Bull | 25% | 92–100 (midpoint 97.6) | +37% ~ +49% | CM310 peak RMB 5.5bn with full PN/pediatric AD ramp; CMG901 USD 5bn/10% plus 1L expansion; CM512 wins asthma/COPD; STAR Market listing lands |
Probability-weighted fair value ~HKD 66, essentially coinciding with the current price (expected return ~-1.6%) — symmetric odds; direction depends on catalyst delivery rather than valuation mean reversion. External anchors: sell-side targets of HKD 82–110 are all above the current price (+22% to +64%); our base case is below every live sell-side target; the bear case is far below the sell-side floor as an independent stress scenario (competition + regulatory setback), not an extension of sell-side ranges.
Conclusion: fair (fairly priced). Target price range HKD 62–67 (= base-case SOTP; peak ±30% sensitivity range HKD 48.7–80.8). Quality and price assessed separately: quality is first-tier (first-mover + dual-listing + platform monetization + RMB 3.2 billion cash), but the price offers no discount protection. Our own earnings forecast (earnings reconciliation anchor): FY2026 revenue RMB 1.15–1.25 billion (product 0.90–0.96bn + milestones 0.23–0.29bn), net profit attributable RMB 0.8–1.0 billion (including one-offs; recurring -0.3 ~ -0.5bn); FY2027 revenue RMB 1.5–1.8 billion (product 1.3–1.55bn + milestones 0.15–0.25bn), operating loss narrowing to 0–0.3bn — below Kaiyuan Securities' 2027E of RMB 1.624 billion and sell-side ceilings, mainly due to our more conservative milestone recognition pacing.
Market size: China's autoimmune and allergic disease drug market was ~USD 9.0 billion in 2022 (biologics only 20.4%); Frost & Sullivan projects USD 41.5 billion by 2030 with biologics rising to ~60%, a 2022–2030 CAGR of 21.1%. 2030 sub-segments: asthma USD 10.6–10.7 billion, atopic dermatitis (AD) ~USD 7.2 billion (~81.3 million patients, 30% moderate-to-severe), psoriasis USD 9.5–9.9 billion, COPD USD 6.3–7.4 billion. Global autoimmune biologics ~USD 145 billion by 2030. The IL-4Rα ceiling is validated by dupilumab (Dupixent) as a single agent: 2025 global sales of EUR 15.714 billion (~USD 18.3 billion, +25.2%), with Sanofi targeting EUR 25 billion by 2030 — this is Kangyueda's China benchmark: Dupixent China sales of RMB 3.629 billion in 2024, RMB 2.677 billion in the first three quarters of 2025, expected RMB 4.5+ billion for the full year, while China's AD biologics penetration remains only ~3–5% (vs. 10–15% achievable on the US trajectory); CRSwNP biologics were a blank space before 2024, and prurigo nodularis started from zero. CLDN18.2 ADC gastric cancer market: ~183,500 2L+ CLDN18.2-positive/HER2-negative patients per year across the US, Europe, China, and Japan (CLDN18.2≥25% expressers account for ~60% of gastric cancers); AZ guides CMG901 peak sales of USD 3–5 billion. The payment-side inflection is the core variable in this round of demand repricing: the 2025 NRDL negotiation introduced a commercial insurance innovative drug list for the first time (19 drugs admitted, exempt from out-of-pocket ratio assessments) + Stapokibart's NRDL entry in January 2026 + Essential Drugs List entry in July 2026 (effective September 2026, mandatory stocking at county-level facilities) — the volume-for-price transition ramp is already visible in the +227% of the first three quarters of 2026.
Value chain and value distribution: Upstream comprises antibody discovery/CMC and clinical CROs — CM AB has built in-house GMP capacity (21,800+24,000 L, NMPA/FDA dual-compliant) and six technology platforms (nTCE bispecifics, ADC, etc.), with high R&D in-house capability and strong bargaining power upstream; in midstream clinical development, global Phase III costs for oncology assets are borne by buyers such as AZ/Gilead (the USD 1-billion-scale Phase III funding barrier is transferred off the company's books); downstream, on the autoimmune side, are hospital/pharmacy channels + the medical insurance payer (team of 550+, covering 30 provinces, 290 cities, 2,200+ hospitals, 670+ pharmacies), with weak bargaining power vs. the healthcare security administration (RMB 1,039/vial is an NRDL outcome, trading price for volume) — gross profit accrues mainly in the "autoimmune self-developed commercialization" link, while licensing delivers extremely high-margin but one-off revenue.
Supply-demand and competitive landscape: Only 2 IL-4Rα products approved globally (Dupixent, stapokibart), a de facto duopoly in China (CR2=100%) — but loosening in 2027–2028: Genor Biopharma's gebristuzumab (AD Phase III completed, CRSwNP NDA accepted October 2026), Akeso's man於onib (AD NDA accepted), Sunshine Guojian's 611, QuiaTX's QX005N, and Bio-Thera's comekibart are all in the Phase III queue, bringing the domestic count to 4–6; adjacent substitutes include oral JAK1 inhibitors (ivatolimib NDA filed) and IL-13 (Eli Lilly's lebrikizumab NDA accepted). Differentiation buffer in rhinology: stapokibart's CRSwNP is the first domestic biologic, and SAR is the only approved IL-4Rα for prurigo nodularis globally. The CLDN18.2 ADC space is a "two-horse race": CM AB/AZ's CMG901 holds a positive global multicenter Phase III OS topline plus AZ's global commercialization machine; Innovent's IBI343 (Takeda holds ex-China rights) was accepted by NMPA with priority review based on China/Japan Phase IIIs advancing first — Chinese 3L+ first-mover status belongs to Innovent, while global registration and commercialization depth belong to AZ/CM AB; the landscape is more complex than the old "globally unique" narrative. Entry barriers: clinical validation (dual-epitope blocking design), market access (dual-listing + hospital networks require 3+ years to build), and ADC CMC complexity (2–3x that of conventional antibodies).
Cyclicality and regulation: China's innovative drug industry is in an upcycle — 157 license-out deals in 2025, totaling USD 135.655 billion with USD 7 billion upfronts (PharmCube data, vs. USD 51.9 billion/94 deals in 2024), and ~USD 110 billion again in 1H2026; the NewCo model is upgrading, with CM AB-incubated Ouro acquired by Gilead for up to USD 2.175 billion (a China NewCo upfront record). Policy tailwinds: NRDL negotiation success rate at an all-time-high 88% + institutionalized commercial insurance list + STAR Market第五套 standard relaunch (16 biopharma applications accepted in 1H2026). Risks lie in renewal price cuts and pressure on the medical insurance fund. Leading indicators: quarterly BD upfront totals, Kangyueda's QoQ sales, competitor NDA review clocks, CMG901 BLA acceptance status.
Peer comparison:
| Company | 2025 Revenue | Growth | Profitability | Market Cap/Valuation | Key Difference vs. CM AB |
|---|---|---|---|---|---|
| CM AB | RMB 716 million | +67% | Book turnaround in 1H2026 (one-off) | HKD 20.0bn, PS(TTM) 20.4x | Autoimmune first-mover + BD dual wheels; smallest scale, highest elasticity |
| Innovent Biologics | RMB 13.042 billion | +38.4% | First full-year profit in 2025 | PS 9.1x | Platform Biopharma, 20 products, 18x CM AB's scale |
| RemeGen | RMB 3.251 billion | +89.4% | First annual turnaround in 2025 | PS 9.5x | Dual commercialized ADC + autoimmune products; main battlegrounds (SLE/MG) are misaligned |
| Akeso | RMB 3.056 billion | +43.9% | Loss-making (upfront investment) | PS 21.3x | Global FIC oncology bispecifics, reliant on Summit partnership |
| Genor Biopharma | ~RMB 200 million (2025E) | Ramp-up stage | Loss-making | PS ~42x | Most direct domestic IL-4Rα competitor, ~2 years behind, no BD out-licensing |
Company positioning: First tier of domestic autoimmune biotechs (2-year first-mover lead + dual-listing + 6-indication matrix), with overall scale smaller than RemeGen/Innovent; top-tier domestic BD capability (10+ cumulative out-licensing deals, AZ total exceeding USD 1.1 billion, four NewCos). Share trend: currently exclusive in domestic IL-4Rα increment; after competitors enter in 2027–2028, expected to hold 50%+ of domestic share (first-mover + access advantages) — this is the core assumption behind our base-case peak of RMB 4.1 billion and the biggest model risk. One-line positioning: a dual-wheel Biotech as "autoimmune commercialization pioneer + global asset vendor of oncology ADC/bispecifics," transitioning toward Biopharma (planned STAR Market listing).
Pipeline Panorama (core assets, self-owned/licensed labels):
| Asset | Target/Mechanism | Indications and Stage | Rights |
|---|---|---|---|
| CM310 Stapokibart | IL-4Rα mAb | Commercialized (adult AD 2024-09/CRSwNP 2024-12/SAR 2025-02/adolescent AD 2026-10); PN NDA under review (2026-03); pediatric AD Phase III | Self-owned in China; Aeira holds registration & commercialization rights in 18 countries |
| CMG901/AZD0901 | CLDN18.2 ADC | 2L+ gastric cancer Phase III positive OS, US/China BLA 2026Q4; 1L Phase III ongoing | AZ global exclusive; Keymed holds 70% via KYM |
| CM512 | TSLP×IL-13 bispecific | CRSwNP Phase II met all endpoints, Phase III initiated (Q24W); asthma/COPD/AD Phase II | Self-owned in China; Belenos holds ex-China rights (incl. CM536) |
| CM326 | TSLP mAb | Asthma Phase III (first patient 2026-03), CRSwNP Phase III | CSPC Jinmantang Greater China exclusive |
| CM336 | BCMA×CD3 bispecific | RRMM Phase III (combined with CM313); FDA Fast Track for AIHA/ITP; ORR 95.2% | Self-owned in Greater China; ex-China via Ouro to Gilead/Lakefront |
| CM313 | CD38 mAb | ITP Phase II completed, IgA nephropathy Phase II | Self-owned in China; Timberlyne holds ex-China rights |
| CM355 | CD20×CD3 | r/r B-NHL (ORR 82%) Phase II | Split evenly with InnoCare; ex-China Prolium |
Core Asset rNPV (built by this report, discounting base end-2026):
| Asset | Peak Sales Assumption | PoS | Launch Year | rNPV (RMB 100mn) | Peak ±30% Sensitivity |
|---|---|---|---|---|---|
| CM310 | RMB 4.1bn (2033) | 0.90 | Launched | 55.9 | 39.1 / 72.6 |
| CMG901 | USD 4bn (2033-34) ×8% royalty×70% | 0.77 | 2028 (US/China) | 44.1 | 30.9 / 57.3 |
| CM512 | China RMB 1.5bn + ex-China USD 1.5bn (7% royalty) | 0.55/0.40 | 2029/2031 | 13.0 | 9.1 / 16.8 |
| CM326 | CSPC basis RMB 1.5bn (~8% royalty) | 0.50 | 2031 | 3.0 | 2.1 / 3.9 |
| CM336 | Ex-China USD 1bn (royalty + USD 610mn milestone pool) | 0.35 | 2032+ | 9.9 | 6.9 / 12.9 |
| CM313 | Ex-China USD 400mn (8% royalty) | 0.35 | 2029 | 6.2 | 4.3 / 8.1 |
| CM355 | Milestone cap USD 502.5mn ×50% | 0.30 | 2030 | 3.3 | 2.3 / 4.3 |
| Early-stage portfolio | Platform options | — | 2030+ | 3.0 | Bear 0 / Bull 8 |
| SOTP | Pipeline 13.83bn + net cash 2.564bn = RMB 16.40bn ≈ HKD 64.7/share | HKD 48.7–80.8 |
Key assumption disclosure: royalty rates for AZ (CMG901), CSPC (CM326), Belenos (CM512), and Timberlyne (CM313) are undisclosed; 8%/8%/7%/8% are assumptions based on comparable deals (Guosen described CMG901's rate as "low double digits," potentially higher in reality—an upside sensitivity); CM310 net margin of 30% uses a neutral value for biologics at scale; net cash is based on the 2026-06-30 figure, milestone present values are all included in the corresponding asset rNPVs with no double-counting against net cash; the STAR Market offering is not reflected in share count.
Clinical Milestone Calendar (binary events over next 12–24 months): CMG901 US/China BLA submission (2026Q4, per AZ) → FDA acceptance/priority review (2027H1) → approval (2027H2–2028Q1); Stapokibart PN approval (2026-12–2027H1, referencing the ~9.5-month acceptance-to-approval pace for adolescent AD); CM512 CRSwNP Phase III initiation/first patient enrolled (2026Q4–2027Q1) + Belenos global Phase III (2027); CM336 RRMM Phase III initiation in combination with CM313; Gilead contingent milestone up to USD 70mn (2027); Aeira registration milestones in 18 countries (from 2027); STAR Market tutoring acceptance/application (expected 2027H1); 2027Q4 NRDL renewal negotiations (two-way event).
Cash Runway: Net cash of ~RMB 2.564bn at end-2026H1 + undrawn credit facilities of RMB 375mn; based on the 2026H1 burn pace (operating net outflow + CapEx of ~RMB 330mn per half-year), this supports ~47 months, and Q3 single-quarter product revenue of RMB 267mn shows improving operational cash generation—refinancing risk is low; the STAR Market offering is supplementary ammunition, not a survival need.
Competitive Positioning by Mechanism: IL-4Rα—2nd approved globally, 1st domestically, with two exclusive ENT indications and ~2 years of first-mover advantage; TSLP axis—only Tezspire approved globally (USD 1.478bn in 2025), CM512 is the world's first long-acting TSLP×IL-13 bispecific, second in target-class sequence (Kelun-Biotech/HUTCHMED, Innovent in early clinical stage); CLDN18.2 ADC—first to report positive OS topline from a global multicenter registrational Phase III, though China acceptance progress lags Innovent's IBI343 (first-mover competition established); BCMA×CD3—one of the first movers in the autoimmune TCE space (FDA Fast Track + NEJM-published data).
Rating: Neutral, confidence 0.58, time horizon 12 months. Keymed's quality is beyond doubt: autoimmune first-mover status + dual-directory reimbursement access, a BD platform priced and validated four times by MNCs/overseas capital, RMB 3.2bn cash with ~47-month runway, and a dense catalyst calendar over the next 12 months. The issue is only price: at HKD 67.05, the current price trades at a 3.6% premium to this report's base fair value of HKD 64.7, with a margin of safety of roughly -8% (target range floor below current price); probability-weighted fair value of ~HKD 66 coincides with the current price (expected return ~-1.6%)—the market isn't wrong, and we found no evidence of systematic undervaluation; sell-side targets of HKD 82–110 are 22%–64% more optimistic than this report's model, with realization contingent on royalty terms better than assumed and upward peak revisions. Strategy: don't chase at current levels; staged accumulation below HKD 62 (base-case fair value floor) offers value; above HKD 85 (bull-case pricing initiation), execution verification is required.
Risk and Catalyst Alerts: Upside—CMG901 BLA submission/acceptance (2026Q4–2027H1), PN approval, CM512 Phase III initiation, STAR Market acceptance, execution of ~HKD 100mn company share purchases; Downside—BLA information requests/CRL (PFS flaw), price war after IBI343's China approval, single-quarter product revenue below RMB 190mn in Q4 (guidance falsified), NRDL renewal price cuts exceeding 30% in 2027Q4, STAR Market offering dilution of 9–13%. See the watchlist for monitoring: quarterly product revenue, BLA status, competitor review clocks, and renewal negotiations are the four mandatory checks.
This report is based on Keymed Biosciences' 2025 annual report, 2026 interim report, 2026Q1-3 inside-information announcements, and public information as of 2026-11-01; the price anchor is the 2026-10-30 closing price of HKD 67.05. The rNPV/SOTP models are built by this report; undisclosed terms such as royalty rates are explicit assumptions and do not constitute investment advice.